Hauschild A, Santinami M, Long G, et al. COMBI-AD: Adjuvant Dabrafenib (D) Plus Trametinib (T) for Resected Stage III BRAF V600E/K–Mutant Melanoma. ESMO 2017 Congress; abstract LBA6_PR. ,Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. DOI: 10.1056/NEJMoa1708539.
Alectinib versus crizotinib bij ALK-positief NSCLC
jun 2017 | Longoncologie